Fernando Andreu
Chief Executive Officer at 2cureX ApS
Profile
Fernando Andreu is currently the Chief Executive Officer at 2cureX ApS.
Previously, he held the same position at 2cureX AB from 2021 to 2023.
He was also the Chief Executive Officer at Sysmex Inostics GmbH, Indivumed, Inc., and the Chief Business Officer at Indivumed GmbH.
Mr. Andreu received his undergraduate and MBA degrees from ESADE Business School.
Fernando Andreu active positions
| Companies | Position | Start |
|---|---|---|
2cureX ApS
 2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | Chief Executive Officer | 31/12/2020 |
Former positions of Fernando Andreu
| Companies | Position | End |
|---|---|---|
| 2CUREX AB | Chief Executive Officer | 28/12/2023 |
Sysmex Inostics GmbH
 Sysmex Inostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Sysmex Corp., Sysmex Inostics GmbH is a German company that develops advanced genetic testing technologies. The private company is based in Hamburg, Germany. The CEOs are Bhuwnesh Agrawal, Seido Biwa, Mamoru Kubota. The company was founded by Luis Diaz. Sysmex Inostics was acquired by Sysmex Corp. from Indivumed GmbH on September 25, 2013. | Chief Executive Officer | - |
Indivumed GmbH
 Indivumed GmbH Data Processing ServicesTechnology Services Indivumed GmbH engages in the research and development of medical treatment for cancer patients. The firm develops an integrated analytical platform, which links sample sets from cancer patients such as tissue types, serum, plasma, and urine with a web-accessible database. It offers treatment for the people suffering from GI-tract such as colorectal, gastric, pancreatic, breast, and lung cancer. The company was founded by Hartmut Juhl, Carsten Zornig and Peter Layer in April 2002 and is headquartered in Hamburg, Germany. | Corporate Officer/Principal | - |
| Indivumed, Inc. | Chief Executive Officer | - |
Training of Fernando Andreu
| ESADE Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| 2CUREX AB | Health Technology |
| Private companies | 4 |
|---|---|
Indivumed GmbH
Indivumed GmbH Data Processing ServicesTechnology Services Indivumed GmbH engages in the research and development of medical treatment for cancer patients. The firm develops an integrated analytical platform, which links sample sets from cancer patients such as tissue types, serum, plasma, and urine with a web-accessible database. It offers treatment for the people suffering from GI-tract such as colorectal, gastric, pancreatic, breast, and lung cancer. The company was founded by Hartmut Juhl, Carsten Zornig and Peter Layer in April 2002 and is headquartered in Hamburg, Germany. | Technology Services |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | Health Technology |
Sysmex Inostics GmbH
Sysmex Inostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Sysmex Corp., Sysmex Inostics GmbH is a German company that develops advanced genetic testing technologies. The private company is based in Hamburg, Germany. The CEOs are Bhuwnesh Agrawal, Seido Biwa, Mamoru Kubota. The company was founded by Luis Diaz. Sysmex Inostics was acquired by Sysmex Corp. from Indivumed GmbH on September 25, 2013. | Commercial Services |
| Indivumed, Inc. |
- Stock Market
- Insiders
- Fernando Andreu
